Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Status in Breast Cancer: A Focus on Group 4 Using the 2018 ASCO/CAP HER2 Testing Guideline

被引：0
|
作者：
Hoda, Raza [1 ]
Bowman, Anita [2 ]
Zehir, Ahmet [1 ]
Brogi, Edi [1 ,3 ]
Ladanyi, Marc [1 ]
Arcila, Maria [1 ]
Wen, Hannah [1 ]
Ross, Dara [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Yeadon, PA USA
[3] Weill Cornell Med Coll, New York, NY USA
来源：
LABORATORY INVESTIGATION | 2020年 / 100卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
185
引用
收藏
页码：175 / 177
页数：3
相关论文
共 50 条
  • [1] Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Status in Breast Cancer: A Focus on Group 4 Using the 2018 ASCO/CAP HER2 Testing Guideline
    Hoda, Raza
    Bowman, Anita
    Zehir, Ahmet
    Brogi, Edi
    Ladanyi, Marc
    Arcila, Maria
    Wen, Hannah
    Ross, Dara
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 175 - 177
  • [2] Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline
    Hoda, Raza S.
    Bowman, Anita S.
    Zehir, Ahmet
    Razavi, Pedram
    Brogi, Edi
    Ladanyi, Marc
    Arcila, Maria E.
    Wen, Hannah Y.
    Ross, Dara S.
    HISTOPATHOLOGY, 2021, 78 (04) : 498 - 507
  • [3] Testing IHC Equivocal Human Epidermal Growth Factor Receptor 2 (ERBB2/HER2) samples by FISH: Impact of Updated 2013 ASCO/CAP Breast Cancer Guidelines
    Casey, J.
    Bhargava, R.
    Gurda, G. T.
    Surti, U.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 1027 - 1027
  • [4] ERBB2 copy number analysis of invasive breast carcinoma using digital droplet PCR and targeted next-generation sequencing: A focus on 'non-classical' HER2 FISH groups using the 2018 ASCO/CAP HER2 testing guideline
    Yang, S-R
    Bouhlal, Y.
    De La Vega, F. M.
    Ballard, M.
    West, R. B.
    Sibley, R. K.
    Kuo, C. J.
    Vilborg, A.
    Allison, K. H.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Breast Cancer HER2 (ERBB2) Status by Next-Generation Sequencing Compared to Traditional Methods
    Russell, Meaghan K.
    Pantazi, Angeliki
    Lyle, Stephen
    Tse, Julie Y.
    LABORATORY INVESTIGATION, 2018, 98 : 103 - 103
  • [6] Breast Cancer HER2 (ERBB2) Status by Next-Generation Sequencing Compared to Traditional Methods
    Russell, Meaghan K.
    Pantazi, Angeliki
    Lyle, Stephen
    Tse, Julie Y.
    MODERN PATHOLOGY, 2018, 31 : 103 - 103
  • [7] HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
    Wong, Adele
    Bhan, Atul
    Lennerz, Jochen K.
    Brachtel, Elena
    MODERN PATHOLOGY, 2017, 30 : 522A - 522A
  • [8] HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
    Wong, Adele
    Bhan, Atul
    Lennerz, Jochen K.
    Brachtel, Elena
    LABORATORY INVESTIGATION, 2017, 97 : 522A - 522A
  • [9] Impact of the 2018 ASCO/CAP HER2 focused update on human epidermal growth factor receptor-2 (HER2) testing in breast cancer: A retrospective review of a single institutional cohort
    Hicks, D. G.
    D'Aguiar, M.
    Henry, J.
    McMahon, L.
    Buscaglia, B.
    Turner, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    LABORATORY INVESTIGATION, 2019, 99
12345